Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma.
Saved in:
| Title: | Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma. |
|---|---|
| Authors: | Shah NJ; Memorial Sloan Kettering Cancer Center, New York, New York., Ababio Y; Pfizer Inc, New York, New York., Eccleston A; Pfizer Inc, Surrey, United Kingdom., Rao D; Pfizer Inc, La Jolla, California., Kelly SP; Pfizer Inc, New York, New York., Chang J; Pfizer Inc, New York, New York., Lucht S; Cardinal Health Technologies LLC, Dublin, Ohio., Paydar C; Cardinal Health Technologies LLC, Dublin, Ohio., Van Doren BA; Cardinal Health Technologies LLC, Dublin, Ohio., Bland E; Cardinal Health Technologies LLC, Dublin, Ohio., John W; Cardinal Health Technologies LLC, Dublin, Ohio., Giegerich S; Cardinal Health Technologies LLC, Dublin, Ohio., Laney J; Cardinal Health Technologies LLC, Dublin, Ohio., Feinberg B; Cardinal Health Technologies LLC, Dublin, Ohio., Zarrabi KK; Sidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. |
| Source: | JAMA network open [JAMA Netw Open] 2026 May 01; Vol. 9 (5), pp. e2614061. Date of Electronic Publication: 2026 May 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2574-3805 |
|---|---|
| DOI: | 10.1001/jamanetworkopen.2026.14061 |
